10,867 Shares in SPDR S&P Biotech ETF $XBI Purchased by Yahav Achim Ve Achayot Provident Funds Management Co Ltd.

Yahav Achim Ve Achayot Provident Funds Management Co Ltd. acquired a new position in shares of SPDR S&P Biotech ETF (NYSEARCA:XBI) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 10,867 shares of the exchange traded fund’s stock, valued at approximately $1,325,000. SPDR S&P Biotech ETF comprises approximately 3.0% of Yahav Achim Ve Achayot Provident Funds Management Co Ltd.’s holdings, making the stock its 13th largest holding.

A number of other large investors have also added to or reduced their stakes in XBI. JPMorgan Chase & Co. increased its holdings in SPDR S&P Biotech ETF by 27.3% during the third quarter. JPMorgan Chase & Co. now owns 13,538,738 shares of the exchange traded fund’s stock worth $1,356,582,000 after buying an additional 2,900,633 shares during the last quarter. Assetmark Inc. increased its holdings in SPDR S&P Biotech ETF by 1,042,265.6% during the fourth quarter. Assetmark Inc. now owns 635,843 shares of the exchange traded fund’s stock worth $77,528,000 after buying an additional 635,782 shares during the last quarter. Greenwoods Asset Management Hong Kong Ltd. purchased a new stake in SPDR S&P Biotech ETF during the third quarter worth about $55,613,000. Ameriprise Financial Inc. increased its holdings in SPDR S&P Biotech ETF by 123.0% during the second quarter. Ameriprise Financial Inc. now owns 872,796 shares of the exchange traded fund’s stock worth $72,542,000 after buying an additional 481,408 shares during the last quarter. Finally, Main Street Research LLC purchased a new stake in SPDR S&P Biotech ETF during the fourth quarter worth about $43,959,000.

SPDR S&P Biotech ETF Stock Performance

NYSEARCA XBI opened at $132.74 on Friday. SPDR S&P Biotech ETF has a 52-week low of $80.90 and a 52-week high of $139.19. The company has a 50-day simple moving average of $132.53 and a 200 day simple moving average of $127.08. The company has a market capitalization of $8.47 billion, a PE ratio of 11.47 and a beta of 0.85.

SPDR S&P Biotech ETF Company Profile

SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges. The Biotech Index is a modified equal weight index.